Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Russell

Showing results (1061-1070 of 1,120) with videos related to

Pageof 112
Sort By:
Blood Advances|October 25, 2019
Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemiaPaul Milne, Charlotte Wilhelm-Benartzi, Michael R Grunwald, et al.
Bone Marrow Transplantation|March 23, 2010
Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use dataR F Duarte, B E Shaw, P Marín, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2024
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With <i>NPM1</i> and <i>FLT3</i> MutationsNigel H Russell, Charlotte Wilhelm-Benartzi, Jad Othman, et al.
Blood|February 16, 2024
Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remissionJad Othman, Nicola Potter, Adam Ivey, et al.
Oncology and Therapy|June 13, 2022
Patient, Family Member and Physician Perspectives and Experiences with AML Treatment Decision-MakingThomas W LeBlanc, Nigel H Russell, Loriana Hernandez-Aldama, et al.
Bone Marrow Transplantation|February 8, 2005
The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplantsG Gahrton, S Iacobelli, J Apperley, et al.
Leukemia|November 20, 2009
Diverging effects of HLA-DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA allelesB E Shaw, N P Mayor, N H Russell, et al.
Bone Marrow Transplantation|August 30, 2008
Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplantB E Shaw, G J Mufti, S Mackinnon, et al.
Blood|October 25, 2011
The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysisGareth J Morgan, Walter M Gregory, Faith E Davies, et al.
Haematologica|November 8, 2011
Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial resultsGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Pageof 112

Showing results (1061-1070 of 1,120) with videos related to

Sort By:
Pageof 112
Blood Advances|October 25, 2019
Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemiaPaul Milne, Charlotte Wilhelm-Benartzi, Michael R Grunwald, et al.
Bone Marrow Transplantation|March 23, 2010
Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use dataR F Duarte, B E Shaw, P Marín, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2024
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With <i>NPM1</i> and <i>FLT3</i> MutationsNigel H Russell, Charlotte Wilhelm-Benartzi, Jad Othman, et al.
Blood|February 16, 2024
Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remissionJad Othman, Nicola Potter, Adam Ivey, et al.
Oncology and Therapy|June 13, 2022
Patient, Family Member and Physician Perspectives and Experiences with AML Treatment Decision-MakingThomas W LeBlanc, Nigel H Russell, Loriana Hernandez-Aldama, et al.
Bone Marrow Transplantation|February 8, 2005
The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplantsG Gahrton, S Iacobelli, J Apperley, et al.
Leukemia|November 20, 2009
Diverging effects of HLA-DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA allelesB E Shaw, N P Mayor, N H Russell, et al.
Bone Marrow Transplantation|August 30, 2008
Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplantB E Shaw, G J Mufti, S Mackinnon, et al.
Blood|October 25, 2011
The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysisGareth J Morgan, Walter M Gregory, Faith E Davies, et al.
Haematologica|November 8, 2011
Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial resultsGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Pageof 112